Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States

Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States

Abstract Introduction In September 2023 the Food and Drug Administration (FDA) approved an updated mRNA COVID-19 vaccine targeting the XBB.1.5 sublineage. This study evaluates the effectiveness of mRNA-1273.815, a 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine in preventing COVID-19-rela...

Full description

Saved in:
Bibliographic Details
Main Authors: Amanda Wilson, Neloufar Rahai, Ekkehard Beck, Elisha Beebe, Brian Conroy, Daina Esposito, Priya Govil, Hagit Kopel, Tianyi Lu, James Mansi, Morgan A. Marks, Katherine E. Mues, Rohan Shah, Michelle Skornicki, Tianyu Sun, Astra Toyip, Mitra Yousefi, David Martin, Andre B. Araujo
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-12-01
Series:Infectious Diseases and Therapy
Subjects:
MRNA-1273.815
COVID-19 vaccine
Hospitalization
Medically attended COVID-19
Vaccine effectiveness
Online Access:https://doi.org/10.1007/s40121-024-01091-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40121-024-01091-1

Similar Items